Avelumab and Merkel Cell Carcinoma: Examining the Evidence
From General Health Literacy to Targeted Risk Assessment
The legacy of general health and science communication has long provided the public with foundational knowledge about disease prevention, treatment options, and emerging medical research. Within this broad context, audiences have been educated on the importance of understanding risk factors, the role of the immune system, and the continuous evolution of therapeutic interventions. This heritage of accessible, evidence-based information has empowered individuals to engage with complex health topics, from vaccination to cancer biology, without requiring specialized expertise. As this general health framework matures, it naturally extends into more specific domains where environmental and occupational exposures intersect with clinical outcomes. The same principles of risk awareness and scientific literacy that underpin public health education now guide inquiry into how particular substances or workplace conditions may influence disease development. This progression from broad health literacy to targeted exposure assessment represents a logical expansion of the original educational mission. In the context of mass production environments, where workers may encounter a range of chemical and biological agents, the transition from general health awareness to occupational exposure concern becomes particularly relevant. The focus shifts from population-level health guidance to the systematic evaluation of specific agents encountered in industrial settings, including immunotherapeutic compounds used in manufacturing. This pivot maintains the commitment to clear, factual communication while addressing the nuanced risk profiles that arise in occupational contexts.
Avelumab: Mechanism and Therapeutic Role in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is rising (https://pubmed.ncbi.nlm.nih.gov/36450381/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment of metastatic MCC is the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as pembrolizumab or avelumab, which show better overall response rates and longer duration of responses compared with conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).
Causation vs. Treatment: Understanding the Risk Context
The mechanistic pathways linking avelumab to Merkel cell carcinoma are primarily therapeutic rather than causative. Avelumab is designed to treat MCC by blocking PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. However, the evidence indicates that avelumab can be associated with adverse effects, including immune-related adverse events, and that a subset of patients may not respond to treatment or may experience disease progression while on therapy. For patients who are refractory to avelumab, treatment options are limited. Studies have investigated the use of combined ipilimumab plus nivolumab in avelumab-refractory MCC. In a retrospective study at three German academic sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding causation-related considerations for affected patients, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Rather, avelumab is a treatment for MCC. The risk narrative centers on the adequacy of warnings regarding avelumab's potential adverse effects and the possibility of treatment failure or progression. The timeline between exposure and documented harm is relevant in the context of treatment response or lack thereof. For patients who do not respond to avelumab, progression of MCC can occur during or after treatment. The evidence indicates that for avelumab-refractory patients, efficient and safe treatment options are lacking, and combined ipilimumab plus nivolumab may offer a potential salvage therapy (https://pubmed.ncbi.nlm.nih.gov/33439294/). The adequacy of warnings regarding avelumab and MCC is addressed through the drug's prescribing information, which includes data on efficacy and adverse events from clinical trials such as JAVELIN Merkel 200. However, the evidence snippets do not provide specific details on the content of those warnings. In summary, the evidence shows that avelumab is an approved and effective treatment for metastatic MCC, but it is associated with a risk of non-response or progression in about half of patients. The mechanistic pathway is therapeutic, not causative, and the timeline for harm is related to treatment failure or adverse events during therapy. For affected patients, considerations include the potential need for alternative treatments such as combined ipilimumab plus nivolumab in the event of avelumab refractoriness.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a treatment for MCC, not a cause. It works by blocking PD-L1 to enhance the immune response against cancer cells. However, about 50% of patients may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
What are the risks of avelumab treatment for Merkel cell carcinoma?
Avelumab is associated with immune-related adverse events and a risk of non-response or disease progression. Approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who are refractory, alternative treatments like combined ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.